Zacks: Brokerages Set $2.50 Target Price for Pain
Post# of 23083
(Total Views: 343)
Posted On: 04/07/2017 12:25:13 AM
Zacks: Brokerages Set $2.50 Target Price for Pain Therapeutics, Inc. ($PTIE)
April 6th, 2017 - By Jessica Moore - 0 comments
Pain Therapeutics logoPain Therapeutics, Inc. (NASDAQ
TIE) has been assigned an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.
Analysts have set a twelve-month consensus target price of $2.50 for the company, according to Zacks. Zacks has also assigned Pain Therapeutics an industry rank of 91 out of 265 based on the ratings given to its competitors.
Shares of Pain Therapeutics (NASDAQTIE) traded up 16.6147% on Wednesday, hitting $0.8977. 1,926,642 shares of the stock traded hands. The firm’s 50-day moving average is $0.72 and its 200 day moving average is $0.75. Pain Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.00. The firm’s market cap is $41.42 million.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its position in Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 92,358 shares during the last quarter. Spark Investment Management LLC acquired a new position in Pain Therapeutics during the third quarter valued at approximately $119,000. BVF Inc. IL raised its position in Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock valued at $2,278,000 after buying an additional 128,639 shares during the last quarter. Finally, Gabelli Funds LLC raised its position in Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares during the last quarter. Hedge funds and other institutional investors own 44.34% of the company’s stock.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
5 Day Chart for NASDAQTIE
April 6th, 2017 - By Jessica Moore - 0 comments
Pain Therapeutics logoPain Therapeutics, Inc. (NASDAQ
TIE) has been assigned an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating. Analysts have set a twelve-month consensus target price of $2.50 for the company, according to Zacks. Zacks has also assigned Pain Therapeutics an industry rank of 91 out of 265 based on the ratings given to its competitors.
Shares of Pain Therapeutics (NASDAQ
TIE) traded up 16.6147% on Wednesday, hitting $0.8977. 1,926,642 shares of the stock traded hands. The firm’s 50-day moving average is $0.72 and its 200 day moving average is $0.75. Pain Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.00. The firm’s market cap is $41.42 million. A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its position in Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 92,358 shares during the last quarter. Spark Investment Management LLC acquired a new position in Pain Therapeutics during the third quarter valued at approximately $119,000. BVF Inc. IL raised its position in Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock valued at $2,278,000 after buying an additional 128,639 shares during the last quarter. Finally, Gabelli Funds LLC raised its position in Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares during the last quarter. Hedge funds and other institutional investors own 44.34% of the company’s stock.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
5 Day Chart for NASDAQ
TIE
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'